Use of bosentan for digital ulcers related to systemic sclerosis: A real-life retrospective French study of 89 patients treated since specific approval

Scandinavian Journal of Rheumatology

Volumn 43, Issue 5, 2014, Pages 398-402

  Agard, Christian ^a   Carpentier, P H ^b   Mouthon, L ^c   Clerson, P ^d   Gressin, V ^e   Berezne A ^c   Diot, E ^f   Jego, P ^d   Lok, C ^g   Sparsa, A ^h   Chatelus, E ⁱ   Van Kien, A Khau ^j   Quere I ^j   Sibilia, J ⁱ   Hachulla, E ^k  

^a HÔTEL DIEU   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Orgamétrie ^*  (France)

^e Actelion Pharmaceuticals France   (France)

^f CHU BRETONNEAU   (France)

^g AMIENS UNIVERSITY HOSPITAL   (France)

^h DUPUYTREN UNIVERSITY HOSPITAL   (France)

ⁱ HÔPITAL DE HAUTEPIERRE   (France)

^j HÔPITAL SAINT ELOI   (France)

^k UNIV LILLE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ILOPROST; LIVER ENZYME; PHOSPHODIESTERASE V INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; SULFONAMIDE;

ABNORMAL LABORATORY RESULT; ADULT; AMPUTATION; ARTICLE; ASTHENIA; CLINICAL PRACTICE; DISEASE DURATION; DRUG APPROVAL; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FINGER ULCER; FRANCE; GANGRENE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; OSTEITIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; SMOKING; SYSTEMIC SCLEROSIS; VOMITING; AGED; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; DRUG ADMINISTRATION; FINGER; LONGITUDINAL STUDY; MULTICENTER STUDY; TREATMENT OUTCOME; ULCER;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIN RECEPTOR ANTAGONISTS; FEMALE; FINGERS; FRANCE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SMOKING; SULFONAMIDES; TREATMENT OUTCOME; ULCER;

EID: 84921741895     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2014.887768     Document Type: Article

References (17)

1. Hachulla E, Clerson P, Launay D, Lambert M, Morell-Dubois S, Queyrel V, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007;34:2423-30.
2. Mouthon L, Mestre-Stanislas C, Berezne A, Rannou F, Guilpain P, Revel M, et al. Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis 2010;69:214-17.
3. Berezne A, Seror R, Morell-Dubois S, de Menthon M, Fois E, Dzeing-Ella A, et al. Impact of systemic sclerosis on occupational and professional activity with attention to patients with digital ulcers. Arthritis Care Res (Hoboken) 2011;63:277-85.
4. Tiev KP, Diot E, Clerson P, Dupuis-Simeon F, Hachulla E, Hatron PY, et al. Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinerAIR-Sclerodermie). J Rheumatol 2009;36:1470-6.
5. Morelli S, Ferri C, Polettini E, Bellini C, Gualdi GF, Pittoni V, et al. Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 1995;99:255-60.
6. Vancheeswaran R, Azam A, Black C, Dashwood MR. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994;21:1268-76.
7. Leask A. The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis. Pharmacol Res 2011;63:502-3.
8. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
9. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011;70:32-8.
10. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
11. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
12. Roman Ivorra JA, Simeon CP, Alegre Sancho JJ, Egurbide MV, Castillo MJ, Lloria X, et al. Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study. J Rheumatol 2011;38:1631-5.
13. Steen V, Denton CP, Pope JE, Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 2009;48(Suppl 3):iii19-24.
14. Caramaschi P, Martinelli N, Volpe A, Pieropan S, Tinazzi I, Patuzzo G, et al. A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost. Clin Rheumatol 2009;28:807-13.
15. Khimdas S, Harding S, Bonner A, Zummer B, Baron M, Pope J, et al. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry. Arthritis Care Res (Hoboken) 2011;63:142-9.
16. Gaultier JB, Hot A, Cathebras P, Grange C, Ninet J, Rousset H. Systemic sclerosis in men [in French]. Rev Med Interne 2008;29:181-6.
17. Denton CP, Krieg T, Guillevin L, Schwierin B, Rosenberg D, Silkey M, et al. Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. Ann Rheum Dis 2012;71:718-21.